Tin Htwe Thin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tin Htwe Thin has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Rachel Brody
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA
19 shared publications - Monica Garcia-Barros
Icahn School of Medicine at Mount Sinai 7 Department of Pathology New York, New York
18 shared publications - Seunghee Kim-Schulze
Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY
18 shared publications - Adília Hormigo
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
17 shared publications - Brian Hyohyoung Lee
Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea
17 shared publications - Constantinos G. Hadjipanayis
Center for Image-Guided Neurosurgery, Department of Neurological Surgery, University of Pittsburgh Medical Center
17 shared publications
Latest Publications
- 23 September 2026
- Published by Springer Nature in Nature Medicine
- p. 1-13
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy
B cell-targeted therapies are expanding across oncologic and autoimmune indications, yet their consequences for mucosal immunity remain incompletely examined. Here we define the pathophysiology of ciltacabtagene autoleucel chimeric antigen receptor (CAR)-T cell-induced enterocolitis (EC) (CAR-TEC)—a severe complication of B cell maturation antigen-targeted CAR-T cell therapy in multiple myeloma. Using single-cell transcriptomics, flow cytometry and tissue imaging of intestinal biopsies from patients with CAR-TEC (n = 10), CAR-T cell-treated controls without EC (n = 7) and healthy volunteers (n = 26), we identify profound depletion of mucosal B cells and plasma cells accompanied by expansion of highly cytotoxic CAR-T cells and inflammatory myeloid, stromal and glial cell remodeling to be associated with CAR-TEC. Cell–cell communication analyses suggest a compensated mucosal state in CAR-T cell-treated controls, telocyte-driven stromal niche dysfunction as noted in CAR-TEC. Interferon- and Janus kinase (JAK) and signal transducer and activator of transcription-associated reprogramming was noted across stromal, endothelial and epithelial compartments, supporting JAK inhibition as a rational, mechanism-based therapeutic strategy. Upadacitinib—an oral selective JAK 1 inhibitor—resulted in clinical, endoscopic and histologic improvement in two people with CAR-TEC. Our findings define CAR-TEC as a multicompartment syndrome of severe mucosal dysregulation with implications for the emerging field of B cell-targeted therapies.
- 23 September 2026
- Published by Springer Nature in Nature Medicine
- p. 1-13
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy
B cell-targeted therapies are expanding across oncologic and autoimmune indications, yet their consequences for mucosal immunity remain incompletely examined. Here we define the pathophysiology of ciltacabtagene autoleucel chimeric antigen receptor (CAR)-T cell-induced enterocolitis (EC) (CAR-TEC)—a severe complication of B cell maturation antigen-targeted CAR-T cell therapy in multiple myeloma. Using single-cell transcriptomics, flow cytometry and tissue imaging of intestinal biopsies from patients with CAR-TEC (n = 10), CAR-T cell-treated controls without EC (n = 7) and healthy volunteers (n = 26), we identify profound depletion of mucosal B cells and plasma cells accompanied by expansion of highly cytotoxic CAR-T cells and inflammatory myeloid, stromal and glial cell remodeling to be associated with CAR-TEC. Cell–cell communication analyses suggest a compensated mucosal state in CAR-T cell-treated controls, telocyte-driven stromal niche dysfunction as noted in CAR-TEC. Interferon- and Janus kinase (JAK) and signal transducer and activator of transcription-associated reprogramming was noted across stromal, endothelial and epithelial compartments, supporting JAK inhibition as a rational, mechanism-based therapeutic strategy. Upadacitinib—an oral selective JAK 1 inhibitor—resulted in clinical, endoscopic and histologic improvement in two people with CAR-TEC. Our findings define CAR-TEC as a multicompartment syndrome of severe mucosal dysregulation with implications for the emerging field of B cell-targeted therapies.
- 23 September 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (4) , 1139-1143.e5
Safety, Tolerability, and Efficacy of Topical Diphencyprone for Cutaneous Neurofibromas: Results From a Phase I Clinical Trial
- 23 September 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (4) , 1139-1143.e5
Safety, Tolerability, and Efficacy of Topical Diphencyprone for Cutaneous Neurofibromas: Results From a Phase I Clinical Trial
- Open Access
- 10 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (19) , eadm7515
CD8 + T cell targeting of tumor antigens presented by HLA-E
The nonpolymorphic major histocompatibility complex E (MHC-E) molecule is up-regulated on many cancer cells, thus contributing to immune evasion by engaging inhibitory NKG2A/CD94 receptors on NK cells and tumor-infiltrating T cells. To investigate whether MHC-E expression by cancer cells can be targeted for MHC-E–restricted T cell control, we immunized rhesus macaques (RM) with rhesus cytomegalovirus (RhCMV) vectors genetically programmed to elicit MHC-E–restricted CD8 + T cells and to express established tumor-associated antigens (TAAs) including prostatic acidic phosphatase (PAP), Wilms tumor-1 protein, or Mesothelin. T cell responses to all three tumor antigens were comparable to viral antigen-specific responses with respect to frequency, duration, phenotype, epitope density, and MHC restriction. Thus, CMV-vectored cancer vaccines can bypass central tolerance by eliciting T cells to noncanonical epitopes. We further demonstrate that PAP-specific, MHC-E–restricted CD8 + T cells from RhCMV/PAP-immunized RM respond to PAP-expressing HLA-E + prostate cancer cells, suggesting that the HLA-E/NKG2A immune checkpoint can be exploited for CD8 + T cell–based immunotherapies.
- 10 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (19) , eadm7515
Open AccessCD8 + T cell targeting of tumor antigens presented by HLA-E
The nonpolymorphic major histocompatibility complex E (MHC-E) molecule is up-regulated on many cancer cells, thus contributing to immune evasion by engaging inhibitory NKG2A/CD94 receptors on NK cells and tumor-infiltrating T cells. To investigate whether MHC-E expression by cancer cells can be targeted for MHC-E–restricted T cell control, we immunized rhesus macaques (RM) with rhesus cytomegalovirus (RhCMV) vectors genetically programmed to elicit MHC-E–restricted CD8 + T cells and to express established tumor-associated antigens (TAAs) including prostatic acidic phosphatase (PAP), Wilms tumor-1 protein, or Mesothelin. T cell responses to all three tumor antigens were comparable to viral antigen-specific responses with respect to frequency, duration, phenotype, epitope density, and MHC restriction. Thus, CMV-vectored cancer vaccines can bypass central tolerance by eliciting T cells to noncanonical epitopes. We further demonstrate that PAP-specific, MHC-E–restricted CD8 + T cells from RhCMV/PAP-immunized RM respond to PAP-expressing HLA-E + prostate cancer cells, suggesting that the HLA-E/NKG2A immune checkpoint can be exploited for CD8 + T cell–based immunotherapies.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Table TS1 from A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
Table S1. Representativeness of Study Participants
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable TS1 from A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
Table S1. Representativeness of Study Participants
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Suppl Fig FS2 from A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
Chromogenic multiplex expression analysis of different biomarkers in formalin-fixed paraffin-embedded tissue of a patient's tumor when diagnosed with glioblastoma (34369), before treated with LITT (34370) and after treatment with LITT and avelumab (34371) and quantitative analysis using Halo® Image Analysis Platform.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig FS2 from A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
Chromogenic multiplex expression analysis of different biomarkers in formalin-fixed paraffin-embedded tissue of a patient's tumor when diagnosed with glioblastoma (34369), before treated with LITT (34370) and after treatment with LITT and avelumab (34371) and quantitative analysis using Halo® Image Analysis Platform.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Table TS3 from A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
Tumor molecular characteristics
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable TS3 from A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
Tumor molecular characteristics
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Suppl Fig FS3 from A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
Chromogenic multiplex expression analysis of different biomarkers in formalin-fixed paraffin-embedded tissue of 34364, 34368, 34369, 34370, and 34371 tumors and quantitative analysis using Halo® Image Analysis Platform
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig FS3 from A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
Chromogenic multiplex expression analysis of different biomarkers in formalin-fixed paraffin-embedded tissue of 34364, 34368, 34369, 34370, and 34371 tumors and quantitative analysis using Halo® Image Analysis Platform
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Table TS2 from A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
Table S2. Key Antibodies Resource
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable TS2 from A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma
Table S2. Key Antibodies Resource